Quantcast

Industry news that matters to you.  Learn more

Archives for March 2015

Cancer Network Highlights Top Stories From the 2015 ASCO GI Cancers Symposium

UBM Medica US announces that Cancer Network, a leading online community for oncologists and health care professionals who treat cancer, presents coverage of the 2015 ASCO Gastrointestinal Cancers Symposium, held last month in San Francisco.

Luminex Technology Selected by Assurex Health

Luminex Corporation (NASDAQ: LMNX) recently announced that its xTAG® Technology has been selected for use in enhancing the processing speed and capacity of Assurex Health’s patented GeneSight® tests. 

Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer

Caris Life Sciences® today announced the presentation of study data in small cell cervical cancer (SCCC) that shows multiplatform tumor profiling using Caris Molecular Intelligence®, the company’s panomic, comprehensive tumor profiling service, identified high expressions of certain gene mutations which may explain sensitivities and resistance to common drug therapies. Researchers found that identification of certain biomarkers may guide treatment strategies in rare, aggressive and difficult to treat gynecological cancers. The data was presented during Poster Session B on Sunday, March 29, at the Society of Gynecologic Oncology (SGO) annual meeting on Women’s Cancers in Chicago, Ill.

Caris Molecular Intelligence Facilitates Comparison of Biomarker Profiles to Inform Targeted Treatment Strategies in Distinct Gynecological Cancers

Caris Life Sciences® today announced the presentation of two studies in which Caris Molecular Intelligence®, the company’s panomic, comprehensive tumor profiling service, found that molecular similarities and differences between several rare and difficult to treat gynecological cancers may inform targeted treatment strategies that have the potential to improve patient outcomes. These studies were presented today during Poster Session B at the Society of Gynecologic Oncology (SGO) 2015 Annual Meeting on Women’s Cancer in Chicago, Ill.

Caris Life Sciences’ Multiplatform Tumor Profiling Technology Identifies Expression of PD-1 and PD-L1 in Gynecologic Malignancies

Caris Life Sciences® today announced the presentation of important study data showing the presence of PD-1 and PD-L1 expressing cells in 1,599 gynecologic cancer samples. Using Caris Molecular Intelligence®, the company’s panomic comprehensive tumor profiling service, researchers identified expression of programmed cell death protein-1 (PD-1) in all gynecologic cancers independent of histology while its ligand (PD-L1) expression was variable across malignancies and histologies. This data, along with two separate studies utilizing Caris Molecular Intelligence in the identification of druggable biomarkers in cervical cancers, were presented today during Poster Session B, at the Society of Gynecologic Oncology 2015 Annual Meeting on Women’s Cancers in Chicago, Ill.